Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model
J. Clin. Invest. 118:9 doi:10.1172/JCI34764
[Go to this article.]
Options: View larger image (or click on image)
Medium
Figure 5
Combination therapy is antitumorigenic for treatment of androgen-independent prostate cancer in Nkx3.1; Pten mutant mice.

Comparison of the consequences of single agent versus combination therapy for treatment of androgen-dependent (AD) or androgen-independent (EH) mutant mice. (A and E) Diagram of the experimental strategy, as per Figure 1. (B and F) Prostate tissue weights, showing mean ± SEM, with P value indicated. (C and G) Percentage of proliferating cells as determined by Ki67 staining, showing mean ± SEM, with P value indicated. (D and H) Western blots of protein extracts from prostate tissues following treatment. Western blotting was done using a minimum of 3 independent mice in each group; representative data are shown; total ERK is shown as a control for protein loading.